Run for injury repair

KLOW

Fixed-ratio blendintermediate8 weeks

A fixed four-peptide healing blend sold in a single vial: GHK-Cu, BPC-157, TB-500 and KPV. It is the older GLOW blend (GHK-Cu + BPC-157 + TB-500) with KPV added, which is where the leading K comes from. Run as one daily subcutaneous shot for soft-tissue repair, gut and skin work.

Duration8 wk

Compounds4

Ratio-locked4 of 4

Off standalone rangenone

Also sold as KLOW Blend, GLOW + KPV.

What the ratio costs you

4 of these 4 compounds come out of one vial.

You cannot dose them independently. Every draw moves all 4 together in a ratio fixed by whoever filled the vial, so the only way to raise the component you care about is to raise the others with it.

The ratio is fixed in the vial. Titrating one component means titrating all four, so if the copper load is too high for you the whole stack has to come down.
Blends cannot be split. If you react badly you will not know which of the four caused it, which is the main argument for running the components separately first.

Cautions — 6 on record

Read before running any of this

GHK-Cu delivers copper. Chronic high-dose use alongside a copper-containing multivitamin can push copper up and zinc down; do not run it continuously without a break.
Not for use in pregnancy.
BPC-157, TB-500, KPV and GHK-Cu are all unapproved for injection in humans; every KLOW vial is research-chemical grade with no pharmacy oversight of purity or content.
Do not run it with an active malignancy. Several components are pro-angiogenic or pro-proliferative in animal models.

The 2 fixed-ratio cautions are printed above, at the top of the page.

Components

What is in it, and when

Compound	Dose	Frequency	Time	Notes
GHK-CuRatio-locked	1.25 mg1 mg–2 mg	Once daily7×/week	Evening	The bulk of the blend. Commercial KLOW vials are 80 mg total at 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 / 10 mg KPV, so GHK-Cu is 62.5% of every draw and you cannot dose it independently. GHK-Cu stings and can leave a temporary blue-green mark at the injection site.	Calculator →
BPC-157Ratio-locked	250 mcg200 mcg–500 mcg	Once daily7×/week	Evening	Fixed at one fifth of the GHK-Cu dose by the blend ratio.	Calculator →
TB-500Ratio-locked	250 mcg200 mcg–500 mcg	Once daily7×/week	Evening	Note this is far below the 2-2.5 mg twice-weekly loading dose people use when running TB-500 on its own. The blend ratio makes a real TB-500 load impossible without massively overdosing the GHK-Cu, so add a separate TB-500 vial if loading matters to you.	Calculator →
KPVRatio-locked	250 mcg200 mcg–500 mcg	Once daily7×/week	Evening	The anti-inflammatory arm; an alpha-MSH fragment. Also fixed at one fifth of the GHK-Cu dose.	Calculator →

Doses are per administration, in the canonical unit. The second line under each dose is the range people run. For ratio-locked components the calculator link opens that compound on its own — a blend vial is one draw, so reconstitute against the vial total, not the component.

Delivered dose vs standalone dose

Where each component actually lands

Each bar is that compound’s own dose range from its monograph, with a marker where this protocol puts it. A marker outside the band means the protocol is not dosing that compound the way it is dosed on its own — for a fixed-ratio vial that is arithmetic, not a choice.

GHK-Cu

Ratio-lockedWithin standalone range

Standalone 1 mg–2 mg (typical 1.5 mg)This protocol 1.25 mg

Per dose: 83% of typical
Per week: 8.75 mg · 83% of standalone
Cycle total: 70 mg · 56 doses

The bulk of the blend. Commercial KLOW vials are 80 mg total at 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 / 10 mg KPV, so GHK-Cu is 62.5% of every draw and you cannot dose it independently. GHK-Cu stings and can leave a temporary blue-green mark at the injection site.

BPC-157

Ratio-lockedWithin standalone range

Standalone 200 mcg–500 mcg (typical 250 mcg)This protocol 250 mcg

Per dose: 100% of typical
Per week: 1.75 mg · 100% of standalone
Cycle total: 14 mg · 56 doses

Fixed at one fifth of the GHK-Cu dose by the blend ratio.

TB-500

Ratio-lockedWithin standalone range

Standalone 200 mcg–500 mcg (typical 300 mcg)This protocol 250 mcg

Per dose: 83% of typical
Per week: 1.75 mg · 83% of standalone
Cycle total: 14 mg · 56 doses

Note this is far below the 2-2.5 mg twice-weekly loading dose people use when running TB-500 on its own. The blend ratio makes a real TB-500 load impossible without massively overdosing the GHK-Cu, so add a separate TB-500 vial if loading matters to you.

KPV

Ratio-lockedWithin standalone range

Standalone 200 mcg–500 mcg (typical 500 mcg)This protocol 250 mcg

Per dose: 50% of typical
Per week: 1.75 mg · 50% of standalone
Cycle total: 14 mg · 56 doses

The anti-inflammatory arm; an alpha-MSH fragment. Also fixed at one fifth of the GHK-Cu dose.

Schedule — 8 weeks

Week by week

Dosing weeks for each component of KLOW
Compound	1Week 1	2Week 2	3Week 3	4Week 4	5Week 5	6Week 6	7Week 7	8Week 8	Cycle total
GHK-Cu1.25 mg · 7×/wk									70 mg56 doses
BPC-157250 mcg · 7×/wk									14 mg56 doses
TB-500250 mcg · 7×/wk									14 mg56 doses
KPV250 mcg · 7×/wk									14 mg56 doses

dosing past that compound’s own typical cycle length

This protocol outlasts some of its own components

GHK-Cu is typically cycled for 4 weeks; this protocol runs 8 weeks, so weeks 5–8 are past that. In a fixed-ratio vial you cannot drop it early without dropping everything else with it.
TB-500 is typically cycled for 6 weeks; this protocol runs 8 weeks, so weeks 7–8 are past that. In a fixed-ratio vial you cannot drop it early without dropping everything else with it.

The dataset records one dose per component, so every dosing week is identical. Where a protocol note describes a loading phase followed by maintenance, that phase change is in the note, not in the schedule — read the component notes before assuming the grid is the whole story.

Evidence

What is actually known

VERIFIED COMPOSITION: KLOW is GHK-Cu + KPV + BPC-157 + TB-500 - four peptides, not five. Larazotide is NOT part of it and is not present in any commercial KLOW product checked; it is a separate oral tight-junction agent studied in coeliac disease. Vendor listings, certificates of analysis and protocol write-ups agree on 80 mg vials at 50/10/10/10 mg. There is no clinical trial of the blend as a blend: the evidence base is animal work and small human studies on the individual components, mostly topical for GHK-Cu.

SourcesPubMed

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.